A method for improving the bioavailability of NAD+ derivatives

Through the step-by-step release method of CD38 inhibitor and NMN, the problem of low inhibition efficiency of CD38 inhibitors is solved, and more efficient NAD+ level improvement is achieved, significantly improving the bioavailability of NAD+.

CN116459221BActive Publication Date: 2024-11-19HOBOOMLIFE BIO TECH SHENZHEN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310413132.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-27
Publication Date
2024-11-19
Estimated Expiration
2042-10-27

AI Technical Summary

Technical Problem

In the prior art, CD38 inhibitors require a certain incubation time when inhibiting NAD+ hydrolase activity, resulting in NMN and NAD+ being consumed by CD38, reducing the efficiency of improving NAD+ levels.

Method used

Using the step-by-step release method of CD38 inhibitor and NMN, the step-by-step release rate and time difference between CD38 inhibitor and NMN is optimized to improve the NAD+ level by coating CD38 inhibitor as well as NAD+ derivatives as pill core. .

Benefits of technology

It significantly improves the bioavailability and NAD+ level of NMN, reduces the content of NAD+ derivatives degraded by CD38, and increases the content of NAD+.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004185397560000101
    Figure BDA0004185397560000101
  • Figure BDA0004185397560000102
    Figure BDA0004185397560000102
  • Figure BDA0004185397560000111
    Figure BDA0004185397560000111
Patent Text Reader

Abstract

The present invention proposes a method for improving the bioavailability of NAD+ derivatives. The method is to place a CD38 inhibitor and a NAD+ derivative in the same preparation, control the CD38 inhibitor to be released quickly first, and then release the NAD+ derivative after the CD38 inhibitor takes effect, thereby improving the bioavailability of the NAD+ derivative and further increasing the NAD+ level in the body.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a method for improving the bioavailability of NAD+ derivatives. Background Art

[0002] NAD+ is the full name of oxidized nicotinamide adenine dinucleotide, which exists in all living cells and is a coenzyme for many dehydrogenases. It can transfer H through the pyridine ring in the nicotinamide part. + NAD+ plays a vital role in the tricarboxylic acid cycle (a key step in glucose metabolism) by storing and transporting electrons. NAD+ is also the only ADP ribose donor in the body and is an essential substance for activating enzymes that maintain multiple life activities, such as Sirtuins (a highly conserved family of deacetylases), PARPs (DNA repair enzymes), CD38, and CD157. Therefore, NAD+ is crucial in maintaining cellular energy metabolism, DNA damage repair, and immune regulation. Studies have found that NAD+ levels steadily decay with age, leading to metabolic changes and increased susceptibility to disease. Restoring NAD+ levels in old or sick animals can promote health and prolong life. Preclinical studies have shown that NMN has multiple pharmacological effects in cardiac and cerebral ischemia, Alzheimer's disease, type 2 diabetes and obesity caused by diet and age, all of which are related to NAD+ deficiency.

[0003] Currently, CD38 inhibitors combined with nicotinamide mononucleotide NMN can increase the level of NAD+ in HEK293T cell lines. However, CD38 inhibitors require a certain incubation time to achieve their NAD+ hydrolase activity, and a large amount of NMN and NAD+ are still consumed by CD38 before CD38 is fully inhibited.

[0004] Therefore, how to more efficiently increase NAD+ levels remains to be studied. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0006] NMN stands for Nicotinamide Mononucleotide, a derivative of NAD+. It is found in some fruits, vegetables and poultry and is a naturally occurring substance in the human body. The main function of NMN is to serve as an intermediate in the biosynthesis of the important coenzyme NAD+ in the human body. Supplementing NMN has been shown to enhance NAD+ biosynthesis.

[0007] CD38 is a multifunctional enzyme and the main hydrolase of NAD+ and its precursors. It can metabolize NAD+, NMN, and NR into ADPR and cADPR. CD38 gene removal can prevent age-related NAD+ decline and mitochondrial dysfunction. CD38 on the cell surface accounts for about 90% of the total CD38 in the body. Therefore, NMN supplemented in vitro will be degraded by CD38 on the cell surface during the process of entering the cell, which seriously affects the utilization efficiency of NAD+ by supplementing NMN in vitro.

[0008] In order to improve the bioavailability of NMN, the content of NAD+ can be increased more efficiently. After continuous innovation and experimentation, the inventors have proposed a method for using the step-by-step release of CD38 inhibitors and NMN to achieve a more efficient NAD+ level increase. This method uses CD38 inhibitors and NMN in the same preparation, so that the CD38 inhibitor is first quickly released, and after the CD38 inhibitor takes effect, NMN is released again, thereby significantly improving the bioavailability of NMN. The present invention optimizes the rate and time difference of the step-by-step release of CD38 inhibitors and NMN through formulation design, realizes the subsequent release of NMN after CD38 is fully inhibited, and significantly improves the efficiency of the combined use of CD38 inhibitors and NMN.

[0009] In one aspect of the present invention, the present invention proposes a microsphere. According to an embodiment of the present invention, the microsphere includes a core, the core includes an NAD+ derivative; and a coating, the coating is wrapped on the outer surface of the core, and the coating includes a CD38 inhibitor. The inventors found that using a CD38 inhibitor as a coating and an NAD+ derivative as a core can achieve the purpose of graded release. In addition, the CD38 inhibitor coating is rapidly released in vivo and inhibits cell CD38 expression. During the optimal time period when the CD38 inhibitor inhibits CD38 in the body, the NAD+ derivative core is released, which can be utilized by cells to the greatest extent and efficiently increase the NAD+ level in the body.

[0010] According to an embodiment of the present invention, the microspheres may further include at least one of the following additional technical features:

[0011] According to an embodiment of the present invention, the CD38 inhibitor is selected from at least one of the following: quercetin, apigenin, resveratrol, grape seed extract, strawberry extract and cocoa extract. The inventors found that the above CD38 inhibitor can better inhibit the expression of CD38 in cells.

[0012] It should be noted that the main absorption site of quercetin or apigenin in the human body is the gastrointestinal tract, and the time from release to absorption is about 2 to 4 hours. According to an embodiment of the present invention, the NAD+ derivative is selected from at least one of the following: nicotinamide mononucleotide NMN, nicotinamide riboside NR, nicotinamide NAM and nicotinamide adenine dinucleotide NADH. The inventors found that the use of the above-mentioned NAD+ derivatives can better promote the generation of NAD+.

[0013] According to an embodiment of the present invention, the mass ratio of the CD38 inhibitor to the NAD+ derivative is (0.5-30): (5-300). The inventors found that the use of this mass ratio can make the CD38 inhibitor and NMN release step by step with a suitable time difference, thereby further improving the utilization rate of the NAD+ derivative and significantly increasing the content of NAD+.

[0014] According to an embodiment of the present invention, the pellet core further comprises a controlled-release skeleton excipient, and the coating further comprises a filler.

[0015] According to an embodiment of the present invention, the mass ratio of the CD38 inhibitor to the filler in the coating is 1: 5 to 1: 15. The inventors found that the mass ratio of the CD38 inhibitor to the excipient in this range can give the microspheres a better morphology, improve the stability of the microspheres, and regulate the release rate of the CD38 inhibitor.

[0016] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the filler in the coating is 1:5 to 1:8.5, 1:9 to 1:15.

[0017] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the filler in the coating is 1:5 to 1:10, 1:11.5 to 1:15. The mass ratio of the CD38 inhibitor to the filler in the coating within this range can achieve the best effect of increasing the NAD+ level.

[0018] It should be noted that the filler is selected from at least one of the following: glucose, sucrose, mannitol, xylitol, erythritol and sodium bicarbonate.

[0019] It should be noted that in order to achieve a better rapid release effect of the CD38 inhibitor, a disintegrant may be added to allow the microspheres to disintegrate quickly and accelerate the release of the CD38 inhibitor.

[0020] According to a specific embodiment of the present invention, the disintegrant is selected from at least one of the following: cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose (L-HPC), cross-linked sodium carboxymethyl cellulose, dry starch, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone and effervescent disintegrant.

[0021] It should be noted that in order to give the microspheres a better shape and improve the stability of the microspheres, a binder may also be added.

[0022] According to a specific embodiment of the present invention, the adhesive is selected from at least one of the following: sodium carboxymethyl cellulose, povidone K30, polyethylene glycol 6000, polyvinyl alcohol, polyurethane and polystyrene.

[0023] According to an embodiment of the present invention, the mass ratio of the NAD+ derivative in the pellet core to the controlled-release skeleton excipient is 5:1 to 5:10. The inventors found that the mass ratio of the NAD+ derivative to the excipient in this range can give the microspheres a better morphology, improve the stability of the microspheres, and regulate the release rate of the NAD+ derivative.

[0024] According to a specific embodiment of the present invention, the mass ratio of the NAD+ derivative in the pellet core to the controlled-release skeleton excipient is 5:1 to 5:1.2, 5:1.5 to 5:10.

[0025] According to a specific embodiment of the present invention, the mass ratio of the NAD+ derivative in the pellet core to the controlled release matrix excipient is 5:1 to 5:1.5, 5:2 to 5:10. The mass ratio of the NAD+ derivative in the pellet core to the controlled release matrix excipient within this range can achieve the best effect of increasing the NAD+ level.

[0026] It should be noted that in order to achieve a better sustained-release effect of NAD+ derivatives, a foaming agent can also be added.

[0027] According to a specific embodiment of the present invention, the foaming agent is selected from at least one of the following: sodium bicarbonate, pine oil, cresol oil, terpineol, isobutyl methyl terpineol, methyl amyl alcohol, triethyl 1-oxane, sodium alkylbenzene sulfonate, sodium alkyl sulfate, polyethylene glycol ether and polyol ether.

[0028] According to an embodiment of the present invention, the controlled release skeleton excipient is selected from at least one of the following: a hydrophilic gel skeleton material and a bioerodible skeleton material.

[0029] According to a specific embodiment of the present invention, the hydrophilic gel skeleton material is selected from at least one of the following: sodium carboxymethyl cellulose (CMC-Na), hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), polyvidone (PVP), ethyl cellulose (EC), polyethylene glycol, microcrystalline cellulose, carbomer (acrylic resin), alginate and deacetylated chitosan (chitosan).

[0030] According to a specific embodiment of the present invention, the bioerodible skeleton material is selected from at least one of the following: beeswax, carnauba wax, stearyl alcohol, glyceryl monostearate, cetyl alcohol, stearyl alcohol, octacosanol and rice bran fatty alcohol.

[0031] It should be noted that, according to the embodiment of the present invention, if the microspheres are made of hydrophilic gel skeleton material, the weight ratio of the hydrophilic gel skeleton material in the entire microsphere is 5% to 50%. If the microspheres are made of bioerodible skeleton material, the weight ratio of the bioerodible skeleton material in the entire microsphere is 3% to 20%.

[0032] According to a specific embodiment of the present invention, the filler is selected from at least one of the following: glucose, sucrose, mannitol, xylitol, erythritol and sodium bicarbonate.

[0033] According to an embodiment of the present invention, the mass ratio of the coating to the pellet core is (5-60):100. The inventors found that the use of a mass ratio of the coating to the pellet core within this range can give the microspheres a better morphology, and at the same time can make the release of the coating and the pellet core have a suitable time difference, thereby further improving the utilization rate of the NAD+ derivatives, thereby achieving the effect of increasing the NAD+ level.

[0034] According to an embodiment of the present invention, the peak time difference between the CD38 inhibitor and the NAD+ derivative is at least 0.5 hours. During this time difference, when the rapid-release CD38 inhibitor in the microspheres inhibits CD38 in the body and makes CD38 in the body reach a minimum value, the sustained-release NAD+ derivative in the microspheres is released, which can improve the bioavailability of NAD+ derivatives and reduce the content of NAD+ derivatives degraded by CD38, thereby increasing the NDA+ level.

[0035] According to a specific embodiment of the present invention, the peak time difference between the CD38 inhibitor and the NAD+ derivative is 0.5 to 4 hours, 0.5 to 2 hours or 2 to 4 hours.

[0036] According to a specific embodiment of the present invention, the peak time difference between the CD38 inhibitor and the NAD+ derivative released is 0.5 to 1.5 hours.

[0037] In another aspect of the present invention, the present invention proposes a method for preparing the aforementioned microspheres. According to an embodiment of the present invention, the method comprises: (1) performing a first mixing treatment on a first excipient and an NAD+ derivative to obtain a pellet core; (2) performing a second mixing treatment on a CD38 inhibitor and a second excipient; (3) coating the second mixed product on the surface of the pellet core to obtain the microspheres. The inventors have found that the microspheres prepared by this method can achieve the purpose of graded release of CD38 inhibitors and NAD+ derivatives, thereby increasing the level of NAD+ in cells.

[0038] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:

[0039] According to an embodiment of the present invention, the CD38 inhibitor is selected from at least one of the following: quercetin, apigenin, resveratrol, grape seed extract, strawberry extract and cocoa extract. The inventors found that the above CD38 inhibitor can better inhibit the expression of CD38 in cells.

[0040] It should be noted that the main absorption site of quercetin or apigenin in the human body is the gastrointestinal tract, and the time from release to absorption is about 2 to 4 hours. The metabolic half-life of quercetin is 11 to 28 hours, and the metabolic half-life of apigenin is 91.8 hours.

[0041] According to an embodiment of the present invention, the NAD+ derivative is selected from at least one of the following: nicotinamide mononucleotide NMN, nicotinamide riboside NR, nicotinamide NAM and nicotinamide adenine dinucleotide NADH. The inventors have found that the use of the above-mentioned NAD+ derivatives can better promote the generation of NAD+.

[0042] According to an embodiment of the present invention, the first excipient comprises a controlled release skeleton excipient.

[0043] According to an embodiment of the present invention, the controlled release skeleton excipient includes at least one selected from the following: a hydrophilic gel skeleton material and a bioerodible skeleton material.

[0044] According to a specific embodiment of the present invention, the hydrophilic gel skeleton material is selected from at least one of the following: sodium carboxymethyl cellulose (CMC-Na), hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), polyvidone (PVP), ethyl cellulose (EC), polyethylene glycol, microcrystalline cellulose, carbomer (acrylic resin), alginate and deacetylated chitosan (chitosan).

[0045] According to a specific embodiment of the present invention, the bioerodible skeleton material is selected from at least one of the following: beeswax, carnauba wax, stearyl alcohol, glyceryl monostearate, cetyl alcohol, stearyl alcohol, octacosanol and rice bran fatty alcohol.

[0046] According to an embodiment of the present invention, the second auxiliary material includes a filler.

[0047] According to a specific embodiment of the present invention, the filler is selected from at least one of the following: glucose, sucrose, mannitol, xylitol, erythritol and sodium bicarbonate.

[0048] According to an embodiment of the present invention, the first auxiliary material further includes a foaming agent.

[0049] According to a specific embodiment of the present invention, the foaming agent is selected from at least one of the following: sodium bicarbonate, pine oil, cresol oil, terpineol, isobutyl methyl terpineol, methyl amyl alcohol, triethyl 1-oxane, sodium alkylbenzene sulfonate, sodium alkyl sulfate, polyethylene glycol ether and polyol ether.

[0050] According to an embodiment of the present invention, the second auxiliary material further includes a disintegrant.

[0051] According to a specific embodiment of the present invention, the disintegrant is selected from at least one of the following: cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose (L-HPC), cross-linked sodium carboxymethyl cellulose, dry starch, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone and effervescent disintegrant. According to an embodiment of the present invention, when the second mixed product is wrapped in the ball core, the second mixed product is further subjected to a third mixing process with a binder.

[0052] According to a specific embodiment of the present invention, the adhesive is selected from at least one of the following: sodium carboxymethyl cellulose, povidone K30, polyethylene glycol 6000, polyvinyl alcohol, polyurethane and polystyrene.

[0053] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the NAD+ derivative is (0.5-30): (5-300). The inventors found that the use of a mass ratio of the CD38 inhibitor to the NAD+ derivative in this range can make the CD38 inhibitor and NMN release step by step with a suitable time difference, thereby further improving the utilization rate of the NAD+ derivative, thereby significantly increasing the content of NAD+.

[0054] According to a specific embodiment of the present invention, the mass ratio of the NAD+ derivative to the first auxiliary material is 5: 1 to 5: 10. The inventors found that the mass ratio of the NAD+ derivative to the first auxiliary material in this range can give the microspheres a better morphology, improve the stability of the microspheres, and regulate the release rate of the NAD+ derivative.

[0055] According to a specific embodiment of the present invention, the mass ratio of the NAD+ derivative to the first auxiliary material is 5:1 to 5:1.2, 5:1.5 to 5:10.

[0056] According to a specific embodiment of the present invention, the mass ratio of the NAD+ derivative to the first auxiliary material is 5:1 to 5:1.5, 5:2 to 5:10. The mass ratio of the NAD+ derivative to the first auxiliary material within this range can achieve the best effect of increasing the NAD+ level.

[0057] It should be noted that the first auxiliary material in “the mass ratio of the NAD+ derivative to the first auxiliary material is 5:1 to 5:10” refers to the controlled release skeleton auxiliary material, and the foaming agent is an auxiliary agent in the first auxiliary material and is not essential.

[0058] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the second auxiliary material is 1: 5 to 1: 15. The inventors found that the mass ratio of the CD38 inhibitor to the second auxiliary material in this range can give the microspheres a better morphology, improve the stability of the microspheres, and regulate the release rate of the CD38 inhibitor.

[0059] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the second auxiliary material is 1:5 to 1:8.5, 1:9 to 1:15.

[0060] According to a specific embodiment of the present invention, the mass ratio of the CD38 inhibitor to the second auxiliary material is 1:5 to 1:10, 1:11.5 to 1:15. The mass ratio of the CD38 inhibitor to the second auxiliary material within this range can achieve the best effect of increasing the NAD+ level.

[0061] It should be noted that the second excipient in "the mass ratio of the CD38 inhibitor to the second excipient is 1:5 to 1:15" refers to a filler, and the disintegrant is an auxiliary agent among the excipients and is not essential.

[0062] According to a specific embodiment of the present invention, the weight ratio of the second mixed product to the pellet core is (5-60): 100. The inventors found that the use of the mass ratio of the second mixed product to the pellet core within this range can give the microspheres a better morphology, and at the same time can make the release of the coating and the pellet core have a suitable time difference, thereby further improving the utilization rate of the NAD+ derivatives, thereby achieving the effect of improving the NAD+ level.

[0063] According to a specific embodiment of the present invention, after the first auxiliary material and the NAD+ derivative are subjected to a first mixing treatment, purified water is needed to prepare a soft material so that the first auxiliary material and the NAD+ derivative can be evenly mixed together.

[0064] According to an embodiment of the present invention, before wrapping the second mixed product on the pellet core, the pellet core is further dried to remove excess water from the pellet core, so that the pellet core has a better shape and more stable properties.

[0065] According to a specific embodiment of the present invention, the moisture weight ratio of the pellet core after the drying process is 3-5%.

[0066] According to a specific embodiment of the present invention, the diameter of the pellet core after drying is 0.1-0.2 mm.

[0067] According to a specific embodiment of the present invention, the encapsulation is carried out in a centrifugal granulator.

[0068] In another aspect of the present invention, the present invention provides a microsphere. According to an embodiment of the present invention, the microsphere is prepared by the method described above.

[0069] It should be noted that all the features and advantages described above for the method for preparing microspheres are also applicable to the microspheres and will not be described in detail here.

[0070] In another aspect of the present invention, the present invention proposes the use of the aforementioned microspheres in the preparation of health products or medicines. According to an embodiment of the present invention, the health products or medicines are used to increase NAD+ levels.

[0071] It should be noted that all the features and advantages described above for the aforementioned microspheres are also applicable to this use and will not be described in detail here.

[0072] In another aspect of the present invention, the present invention provides a method for increasing the NAD+ content of cells. According to an embodiment of the present invention, the cells are contacted with a CD38 inhibitor and an NAD+ derivative in sequence. Contacting the cells with the CD38 inhibitor first can reduce the CD38 content in the cells and prevent CD38 from degrading the NAD+ derivatives. Then contacting the cells with the NAD+ derivatives can increase the bioavailability of the NAD+ derivatives, thereby increasing the NAD+ content of the cells.

[0073] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features:

[0074] According to an embodiment of the present invention, the cells are first contacted with the CD38 inhibitor; and after the first contact treatment for at least 0.5 hours, the cells are second contacted with the NAD+ derivative. During this time difference, when the CD38 inhibitor inhibits CD38 in vivo and makes CD38 in vivo reach a minimum value, contact with the NAD+ derivative again can improve the bioavailability of the NAD+ derivative, reduce the content of the NAD+ derivative degraded by CD38, and thus increase the cellular NDA+ level.

[0075] According to an embodiment of the present invention, the CD38 inhibitor is selected from at least one of the following: quercetin, apigenin, resveratrol, grape seed extract, strawberry extract and cocoa extract. The inventors found that the above CD38 inhibitor can better inhibit the expression of CD38 in cells.

[0076] According to an embodiment of the present invention, the NAD+ derivative is selected from at least one of the following: nicotinamide mononucleotide NMN, nicotinamide riboside NR, nicotinamide NAM and nicotinamide adenine dinucleotide NADH. The inventors have found that the use of the above-mentioned NAD+ derivatives can better promote the generation of NAD+.

[0077] According to an embodiment of the present invention, the cells are contacted with the NAD+ derivative for the second time 0.5 to 4 hours, 0.5 to 2 hours, 0.5 to 1.5 hours or 2 to 4 hours after the first contact treatment. During this time difference, when the CD38 inhibitor inhibits CD38 in vivo and makes CD38 in vivo reach a minimum value, contacting with the NAD+ derivative again can improve the bioavailability of the NAD+ derivative, reduce the content of the NAD+ derivative degraded by CD38, and thus increase the NDA+ level.

[0078] According to an embodiment of the present invention, the CD38 inhibitor and the NAD+ derivative are provided in the form of microspheres, and the microspheres are defined as above.

[0079] In another aspect of the present invention, the present invention provides a method for increasing the NAD+ content of cells. According to an embodiment of the present invention, the cells are administered the aforementioned microspheres.

[0080] In another aspect of the present invention, the present invention provides a method for stepwise release of CD38 inhibitors and NAD+ derivatives. According to an embodiment of the present invention, the aforementioned microspheres are used.

[0081] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0083] Figure 1 This is a diagram of the NMN release verification experiment in the controlled-release NMN microspheres groups 1, 2, and 3 according to an embodiment of the present invention;

[0084] Figure 2 This is a diagram of the quercetin release verification experiment in the controlled-release NMN microspheres groups 1, 2, and 3 according to an embodiment of the present invention;

[0085] Figure 3 This is a verification experiment diagram of improving NAD+ levels in groups 1, 2, and 3 of controlled-release NMN microspheres according to an embodiment of the present invention;

[0086] Figure 4 This is a graph showing the NR release verification experiment in four groups of controlled-release NR microspheres according to an embodiment of the present invention;

[0087] Figure 5 This is a graph showing the release verification experiment of apigenin in four groups of controlled-release NR microspheres according to an embodiment of the present invention;

[0088] Figure 6This is a verification experiment diagram of improving NAD+ level in 4 groups of controlled-release NR microspheres according to an embodiment of the present invention;

[0089] Figure 7 This is a diagram of the NMN release verification experiment in the controlled-release NMN microspheres groups 2, 5, and 6 according to an embodiment of the present invention;

[0090] Figure 8 This is a diagram of the quercetin release verification experiment in the controlled-release NMN microspheres groups 2, 5, and 6 according to an embodiment of the present invention;

[0091] Fig. 9 This is a verification experiment diagram of improving NAD+ levels in groups 2, 5, and 6 of controlled-release NMN microspheres according to an embodiment of the present invention;

[0092] Fig.10 NR release verification experiment diagram of controlled-release NR microspheres 4, 7, and 8 according to an embodiment of the present invention;

[0093] Fig.11 This is a graph showing the release verification experiment of apigenin in the controlled-release NR microspheres groups 4, 7, and 8 according to an embodiment of the present invention;

[0094] Fig.12 This is a verification experiment diagram of improving NAD+ levels in groups 4, 7, and 8 of controlled-release NR microspheres according to an embodiment of the present invention;

[0095] Fig.13 This is a diagram of the NMN release verification experiment in the controlled-release NMN microspheres groups 2, 9, and 10 according to an embodiment of the present invention;

[0096] Fig.14 This is a diagram of a quercetin release verification experiment in groups 2, 9, and 10 of controlled-release NMN microspheres according to an embodiment of the present invention;

[0097] Fig.15 This is a verification experiment diagram of improving NAD+ levels in groups 2, 9, and 10 of controlled-release NMN microspheres according to an embodiment of the present invention;

[0098] Fig.16 NR release verification experiment diagram of the controlled release NR microspheres 4, 11, and 12 according to the embodiment of the present invention;

[0099] Fig.17 This is a graph showing the release verification experiment of apigenin in the controlled-release NR microspheres groups 4, 11, and 12 according to an embodiment of the present invention;

[0100] Fig.18 This is a verification experiment diagram of improving NAD+ levels in groups 4, 11, and 12 of controlled-release NR microspheres according to an embodiment of the present invention. DETAILED DESCRIPTION

[0101] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.

[0102] Example 1 Preparation of controlled-release NMN microspheres with different raw material and excipient ratios

[0103] 1. Preparation of controlled release NMN microspheres 1:

[0104] (1) Take 150 g of NMN, 45 g of hydroxypropyl methylcellulose (controlled release matrix material), 15 g of hexadecanol (controlled release matrix material), and 20 g of sodium bicarbonate (foaming agent), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extrusion spheronizer for extrusion, and the sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0105] (2) Take 15 g of quercetin, 176 g of erythritol (filler), and 54 g of cross-linked polyvinylpyrrolidone (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 5 g of sodium carboxymethyl cellulose (binder), prepare a 1% aqueous solution with purified water, and add it to the spray system of the centrifugal granulator.

[0106] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0107] 2. Preparation of controlled release NMN microspheres 2:

[0108] (1) Take 200 g of NMN and 50 g of hydroxypropyl methylcellulose (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extrusion spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0109] (2) Take 20 g of quercetin, 172 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0110] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0111] 3. Preparation of controlled release NMN microspheres 3:

[0112] (1) Take 180 g of NMN, 20 g of sodium carboxymethyl cellulose (controlled release skeleton material), 20 g of hydroxypropyl cellulose (controlled release skeleton material), 20 g of ethyl cellulose (controlled release skeleton material), and 10 g of cross-linked polyvinylpyrrolidone NF (controlled release skeleton material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extrusion spheronizer for extrusion, and the sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0113] (2) Take 18 g of quercetin, 200 g of xylitol (filler), and 22 g of cross-linked sodium carboxymethyl cellulose (disintegrant), mix them evenly, and add them to the powder feeding system of a centrifugal granulator; take 10 g of polyethylene glycol 6000 (binder), prepare a 15% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0114] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, dry the micro-pellets.

[0115] Example 2 Controlled Release NMN Microsphere Release Verification Experiment (Animal Experiment)

[0116] Twelve SD rats weighing about 200g were purchased. After one week of adaptive feeding, the experiment was conducted. The 12 rats were divided into 3 groups, with 4 rats in each group (half male and half female). Group 1 was gavaged with controlled-release NMN microspheres 1, group 2 was gavaged with controlled-release NMN microspheres 2, and group 3 was gavaged with controlled-release NMN microspheres 3. The controlled-release NMN microspheres gavaged with each rat in each group contained the same dose of NMN, which was 100 mg / kg; the controlled-release NMN microspheres gavaged with each rat in each group also contained the same dose of quercetin, which was 10 mg / kg.

[0117] The rats in each group were given blood through the tail vein at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the contents of NMN and quercetin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged. The results of NMN content in blood samples are shown in Tables 1 and Figure 1 The results of quercetin content in blood samples are shown in Table 2 and Figure 2As shown, the peak time difference between quercetin and NMN release in controlled-release NMN microsphere 1 is approximately between 1h-2h, the peak time difference between quercetin and NMN release in controlled-release NMN microsphere 2 is approximately between 0.5h-1.5h, and the peak time difference between quercetin and NMN release in controlled-release NMN microsphere 3 is approximately between 0h-1h.

[0118] Table 1

[0119]

[0120] Table 2

[0121]

[0122] Example 3: Controlled-release NMN microspheres significantly increase NAD+ levels (animal experiment)

[0123] 28 SD rats weighing about 200g were purchased, and the experiment was conducted after one week of adaptive feeding. The 28 rats were divided into 7 groups, with 4 rats in each group (half male and half female). Group 1 received no treatment, Group 2 was gavaged with 100mg / kg NMN, Group 3 was gavaged with 10mg / kg quercetin, Group 4 was gavaged with 100mg / kg NMN and 10mg / kg quercetin at the same time, Group 5 was gavaged with controlled-release NMN microspheres 1 containing 100mg / kg NMN and 10mg / kg quercetin, Group 6 was gavaged with controlled-release NMN microspheres 2 containing 100mg / kg NMN and 10mg / kg quercetin, and Group 7 was gavaged with controlled-release NMN microspheres 3 containing 100mg / kg NMN and 10mg / kg quercetin.

[0124] Blood was collected from the tail vein of each group of rats at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Tables 3 and Figure 3As shown: With the increase of time, compared with the blank group, the NMN group, quercetin group, NMN+quercetin group, controlled-release NMN microsphere group 1, controlled-release NMN microsphere group 2, and controlled-release NMN microsphere group 3 gavage treatment groups can increase the NAD+ level in rats. Among them, the effect of NMN+quercetin combined administration on increasing NAD+ level is better than that of NMN and quercetin alone; the effect of controlled-release NMN microsphere 1, controlled-release NMN microsphere 2, and controlled-release NMN microsphere 3 on increasing NAD+ is significantly better than that of NMN+quercetin combined administration; the effect of controlled-release NMN microsphere 2 on increasing NAD+ is better than that of controlled-release NMN microsphere 1 and controlled-release NMN microsphere 3. Due to the different parameter settings in the preparation process of controlled-release NMN microspheres 1, controlled-release NMN microspheres 2, and controlled-release NMN microspheres 3, the time intervals between the peak release of quercetin and the peak release of NMN in the microspheres are different. The peak time difference between quercetin and NMN in controlled-release NMN microspheres 1 is between 1h-2h, the peak time difference between quercetin and NMN in controlled-release NMN microspheres 2 is between 0.5h-1.5h, and the peak time difference between quercetin and NMN in controlled-release NMN microspheres 3 is between 0h-1h. Controlled-release NMN microspheres 1 and 2 have the best effect on increasing NAD+ in rats.

[0125] Therefore, from the long-term results, the time-difference release of quercetin and NMN is better than the simultaneous use of quercetin + NMN in increasing the effect of NAD+ in the body, and the optimal time difference is between 0.5h-1.5h.

[0126] Table 3

[0127]

[0128] Example 4 Preparation of controlled release NR microspheres

[0129] Using the preparation process of the controlled-release NMN microspheres 2 in Example 1, NR was used to replace NMN, and apigenin was used to replace quercetin to prepare controlled-release NR microspheres 4. The specific steps are as follows:

[0130] (1) Take 200 g of NR and 50 g of hypromellose (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0131] (2) Take 20 g of apigenin, 172 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0132] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0133] Example 5 Controlled Release NR Microsphere Release Verification Experiment (Animal Experiment)

[0134] Four SD rats weighing about 200 g (half male and half female) were purchased and gavaged with 4 controlled-release NR microspheres. The controlled-release NR microspheres gavaged to each rat contained the same NR dose, which was 100 mg / kg; the controlled-release NR microspheres gavaged to each rat also contained the same apigenin dose, which was 10 mg / kg.

[0135] Each rat was given the corresponding microspheres and blood was collected from the tail vein at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage. The blood volume was 0.1ml each time. The venous blood taken from each rat at each time point was processed and the contents of NR and apigenin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of the four rats were averaged. The results of the NR content in the blood are shown in Tables 4 and Figure 4 As shown in Table 4 and Figure 5 As shown, the peak time difference between apigenin and NR release in controlled-release NR microspheres 4 is approximately between 0.5h and 1.5h.

[0136] Table 4

[0137] 2h 2.5h 3h 3.5h 4h 4.5h 5h 5.5h 6h NR content in blood (μM) 1760 1610 2016 2392 2901 2217 2029 1905 1866 Apigenin content in blood (μM) 0 21.05 43.76 38.54 28.26 31.51 22.63 15.89 9.28

[0138] Example 6: Controlled Release NR Microspheres Significantly Improve NAD+ Levels Verification Experiment (Animal Experiment)

[0139] Twenty SD rats weighing about 200 g were purchased and fed adaptively for one week before the experiment. The 20 rats were divided into five groups, with four rats in each group (half male and half female). Group 1 received no treatment, Group 2 received oral administration of 100 mg / kg NR, Group 3 received oral administration of 10 mg / kg apigenin, Group 4 received oral administration of 100 mg / kg NR and 10 mg / kg apigenin at the same time, and Group 5 received oral administration of controlled-release NR microspheres containing 100 mg / kg NR and 10 mg / kg apigenin.

[0140] Blood was collected from the tail vein of each group of rats at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Tables 5 and Figure 6As shown: As time goes by, compared with the blank group, the NR group, apigenin group, NR+apigenin group, and controlled-release NR microsphere 4 gavage treatment group can all increase the NAD+ level in rats. Among them, the effect of NR+apigenin combined administration on increasing NAD+ level is better than that of NR and apigenin alone, and the effect of controlled-release NR microsphere 4 on increasing NAD+ is significantly better than that of NR+apigenin combined administration.

[0141] Therefore, from the long-term results, the time-delayed release of apigenin and NR in increasing the effect of NAD+ in the body is better than the simultaneous use of apigenin + NR.

[0142] Table 5

[0143]

[0144] Example 7 Preparation of controlled-release NMN microspheres with different mass ratios of CD38 inhibitor quercetin and NMN

[0145] 1. Preparation of controlled release NMN microspheres 5:

[0146] The preparation process of controlled-release NMN microspheres 2 in Example 1 was used, and the mass ratio of CD38 inhibitor quercetin to NMN was changed to 0.5:5, and the ratio of other excipients remained unchanged to prepare controlled-release NMN microspheres 5, and the specific steps were as follows:

[0147] (1) Take 5 g of NMN and 1.25 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0148] (2) Take 0.5 g of quercetin, 4.3 g of mannitol (filler), and 0.15 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 0.1 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0149] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0150] 2. Preparation of controlled release NMN microspheres 6:

[0151] Using the preparation process of controlled-release NMN microspheres 2 in Example 1, the mass ratio of CD38 inhibitor quercetin to NMN was changed to 30:300, and the ratio of other auxiliary materials remained unchanged to prepare controlled-release NMN microspheres 6, and the specific steps were as follows:

[0152] (1) Take 300 g of NMN and 75 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0153] (2) Take 30 g of quercetin, 258 g of mannitol (filler), and 9 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 3 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0154] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0155] Example 8 Release verification experiment of controlled-release NMN microspheres with different mass ratios of CD38 inhibitor quercetin and NMN (animal experiment)

[0156] Twelve SD rats weighing about 200g were purchased. After one week of adaptive feeding, the experiment was conducted. The 12 rats were divided into 3 groups, with 4 rats in each group (half male and half female). Group 1 was gavaged with controlled-release NMN microspheres 2, Group 2 was gavaged with controlled-release NMN microspheres 5, and Group 3 was gavaged with controlled-release NMN microspheres 6. The controlled-release NMN microspheres gavaged with each rat in each group contained the same dose of NMN, which was 100 mg / kg; the controlled-release NMN microspheres gavaged with each rat in each group also contained the same dose of quercetin, which was 10 mg / kg.

[0157] The rats in each group were given blood through the tail vein at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the contents of NMN and quercetin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged. The results of NMN content in blood samples are shown in Tables 6 and Figure 7 The results of quercetin content in blood samples are shown in Table 7 and Figure 8 As shown, there is a peak time difference in the release of quercetin and NMN in the controlled release NMN microspheres 2, controlled release NMN microspheres 5 and controlled release NMN microspheres 6 prepared with different mass ratios of CD38 inhibitor quercetin and NMN, and the peak time difference of quercetin and NMN release in these three microspheres is consistent, all about 0.5h-1.5h.

[0158] Table 6

[0159]

[0160] Table 7

[0161]

[0162] Example 9: Experimental verification that CD38 inhibitor quercetin and NMN controlled-release NMN microspheres with different mass ratios significantly increase NAD+ levels (animal experiment)

[0163] 28 SD rats weighing about 200g were purchased, and the experiment was conducted after one week of adaptive feeding. The 28 rats were divided into 7 groups, with 4 rats in each group (half male and half female). Group 1 received no treatment, Group 2 was gavaged with 100mg / kg NMN, Group 3 was gavaged with 10mg / kg quercetin, Group 4 was gavaged with 100mg NMN / kg and 10mg / kg quercetin at the same time, Group 5 was gavaged with controlled-release NMN microspheres 2 containing 100mg / kg NMN and 10mg / kg quercetin, Group 6 was gavaged with controlled-release NMN microspheres 5 containing 100mg / kg NMN and 10mg / kg quercetin, and Group 7 was gavaged with controlled-release NMN microspheres 6 containing 100mg / kg NMN and 10mg / kg quercetin.

[0164] Blood was collected from the tail vein of each group of rats at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Table 8 and Fig. 9 As shown: With the increase of time, compared with the blank group, the NMN group, quercetin group, NMN+quercetin group, controlled-release NMN microsphere group 1, controlled-release NMN microsphere group 2, and controlled-release NMN microsphere group 3 gavage treatment groups can all increase the NAD+ level in rats at a certain time point. Among them, the effect of NMN+quercetin combined administration on increasing NAD+ level is better than that of NMN and quercetin alone; the effect of controlled-release NMN microsphere 2, controlled-release NMN microsphere 5, and controlled-release NMN microsphere 6 on increasing NAD+ is significantly better than that of NMN+quercetin combined administration; and there is no significant difference in the effect of controlled-release NMN microsphere 2, controlled-release NMN microsphere 5, and controlled-release NMN microsphere 6 on increasing NAD+. Since there is a peak time difference in the release of quercetin and NMN in controlled release NMN microspheres 2, controlled release NMN microspheres 5 and controlled release NMN microspheres 6 prepared with different mass ratios of CD38 inhibitor quercetin and NMN, and the peak time difference of quercetin and NMN release in these three microspheres is consistent, all about 0.5h-1.5h, and there is no significant difference in the effect of controlled release NMN microspheres 2, controlled release NMN microspheres 5 and controlled release NMN microspheres 6 in increasing NAD+.

[0165] Therefore, from the long-term results, the mass ratio of CD38 inhibitor quercetin and NMN is in the range of (0.5-30): (5-300). There is an obvious time difference in the peak release of quercetin and NMN in the microspheres, and the effect of increasing NAD+ is significant, so it is a reasonable ratio range.

[0166] Table 8

[0167]

[0168] Example 10 Preparation of controlled-release NR microspheres with different mass ratios of CD38 inhibitor apigenin and NR

[0169] 1. Preparation of controlled release NR microspheres 7:

[0170] The preparation process of controlled-release NR microspheres 4 in Example 4 was used, and the mass ratio of CD38 inhibitor apigenin to NR was changed to 0.5:5, and the ratio of other auxiliary materials remained unchanged to prepare controlled-release NR microspheres 7, and the specific steps were as follows:

[0171] (1) Take 5 g of NR and 1.25 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0172] (2) Take 0.5 g of apigenin, 4.3 g of mannitol (filler), and 0.15 g of L-HPC (disintegrant), mix well, and add to the powder feeding system of the centrifugal granulator; take 0.1 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0173] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0174] 2. Preparation of controlled release NR microspheres 8:

[0175] The preparation process of controlled-release NR microspheres 4 in Example 4 was used, and the mass ratio of CD38 inhibitor apigenin to NR was changed to 30:300, and the ratio of other auxiliary materials remained unchanged to prepare controlled-release NR microspheres 8, and the specific steps were as follows:

[0176] (1) Take 300 g of NR and 75 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0177] (2) Take 30 g of apigenin, 258 g of mannitol (filler), and 9 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 3 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0178] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0179] Example 11 Release verification experiment (animal experiment) of the preparation of controlled release NR microspheres with different mass ratios of CD38 inhibitor apigenin and NR

[0180] Twelve SD rats weighing about 200g were purchased, and the experiment was conducted after one week of adaptive feeding. The 12 rats were divided into 3 groups, with 4 rats in each group (half male and half female). The first group was gavaged with controlled-release NR microspheres 4, the second group was gavaged with controlled-release NR microspheres 7, and the third group was gavaged with controlled-release NR microspheres 8. The controlled-release NR microspheres gavaged with each rat in each group contained the same dose of NR, which was 100 mg / kg; the controlled-release NR microspheres gavaged with each rat in each group also contained the same dose of apigenin, which was 10 mg / kg.

[0181] The rats in each group were respectively gavaged with the corresponding microspheres at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h through the tail vein blood, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the contents of NR and apigenin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged. The results of NR content in the blood are shown in Tables 9 and Fig.10 As shown in Table 10 and Fig.11 As shown, there is a peak time difference in the release of apigenin and NR in the controlled release NR microspheres 2, 7 and 8 prepared with different mass ratios of CD38 inhibitor apigenin and NR, and the peak time difference in the release of apigenin and NR in these three microspheres is consistent, all about 0.5h-1.5h.

[0182] Table 9

[0183]

[0184] Table 10

[0185]

[0186] Example 12: Experimental verification (animal experiment) on the significant improvement of NAD+ levels by controlled-release NR microspheres containing different mass ratios of CD38 inhibitor apigenin and NR

[0187] 28 SD rats weighing about 200 g were purchased, and the experiment was conducted after one week of adaptive feeding. The 28 rats were divided into 7 groups, with 4 rats in each group (half male and half female). Group 1 was not treated, Group 2 was gavaged with 100 mg / kg NR, Group 3 was gavaged with 10 mg / kg apigenin, Group 4 was gavaged with 100 mg / kg NR and 10 mg / kg apigenin at the same time, Group 5 was gavaged with controlled-release NR microspheres 4 containing 100 mg / kg NR and 10 mg / kg apigenin, Group 6 was gavaged with controlled-release NR microspheres 7 containing 100 mg / kg NR and 10 mg / kg apigenin, and Group 7 was gavaged with controlled-release NR microspheres 8 containing 100 mg / kg NR and 10 mg / kg apigenin.

[0188] The rats in each group were given blood through the tail vein at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Tables 11 and Fig.12 As shown: Compared with the blank group, the NR group, apigenin group, NR+apigenin group, controlled-release NR microsphere group 4, controlled-release NR microsphere group 7, and controlled-release NR microsphere group 8 gavage treatment groups can all increase the NAD+ level in rats at a certain time point. Among them, the effect of NR+apigenin combined administration on increasing NAD+ level is better than that of NR and apigenin alone; the effects of controlled-release NR microspheres 2, controlled-release NR microspheres 7, and controlled-release NR microspheres 8 on increasing NAD+ are significantly better than those of NR+apigenin combined administration; and there is no significant difference in the effects of controlled-release NR microspheres 2, controlled-release NR microspheres 7, and controlled-release NR microspheres 8 on increasing NAD+. Since there is a peak time difference in the release of apigenin and NR in the controlled release NR microspheres 2, controlled release NR microspheres 7 and controlled release NR microspheres 8 prepared with different ratios of CD38 inhibitor apigenin and NR, and the peak time difference of apigenin and NR release in these three microspheres is consistent, all of which are 0.5h-1.5h, and there is no significant difference in the effect of controlled release NR microspheres 2, controlled release NR microspheres 7 and controlled release NR microspheres 8 in increasing NAD+.

[0189] Therefore, the mass ratio of CD38 inhibitor apigenin to NR is in the range of (0.5-30): (5-300). There is an obvious time difference in the peak release of apigenin and NR in the microspheres, and the effect of increasing NAD+ is significant, so it is a reasonable mass ratio range.

[0190] Table 11

[0191]

[0192] Example 13 Preparation of controlled-release NMN microspheres with different ratios of CD38 inhibitor quercetin and excipients and different mass ratios of NMN and excipients

[0193] 1. Preparation of controlled release NMN microspheres 9:

[0194] The preparation process of controlled-release NMN microspheres 2 in Example 1 was used, and the mass ratio of CD38 inhibitor quercetin to mannitol was changed to 1:5; the ratio of NMN to hydroxypropyl methylcellulose was 5:1, and controlled-release NMN microspheres 9 were prepared. The specific steps are as follows:

[0195] (1) Take 200 g of NMN and 40 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0196] (2) Take 20 g of quercetin, 100 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0197] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0198] 2. Preparation of controlled release NMN microspheres 10:

[0199] Using the preparation process of the controlled-release NMN microspheres 2 in Example 1, the mass ratio of CD38 inhibitor quercetin to mannitol was 1:15; the mass ratio of NMN to hydroxypropyl methylcellulose was 5:10, and the controlled-release NMN microspheres 10 were prepared. The specific steps are as follows:

[0200] (1) Take 200 g of NMN and 400 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0201] (2) Take 20 g of quercetin, 300 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix them evenly, and add them to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0202] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0203] Example 14 Release verification experiment of controlled-release NMN microspheres with different ratios of CD38 inhibitor quercetin and excipients and different mass ratios of NMN and excipients (animal experiment)

[0204] Twelve SD rats weighing about 200g were purchased. After one week of adaptive feeding, the experiment was conducted. The 12 rats were divided into 3 groups, with 4 rats in each group (half male and half female). Group 1 was gavaged with controlled-release NMN microspheres 2, Group 2 was gavaged with controlled-release NMN microspheres 9, and Group 3 was gavaged with controlled-release NMN microspheres 10. The controlled-release NMN microspheres gavaged with each rat in each group contained the same dose of NMN, which was 100 mg / kg; the controlled-release NMN microspheres gavaged with each rat in each group also contained the same dose of quercetin, which was 10 mg / kg.

[0205] The rats in each group were respectively gavaged with the corresponding microspheres at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h through the tail vein, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the contents of NMN and quercetin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged. The results of NMN content in blood samples are shown in Tables 12 and Fig.13 The results of quercetin content in blood samples are shown in Table 13 and Fig.14 As shown, there is a peak time difference in the release of quercetin and NMN in the controlled release NMN microspheres 2, 9 and 10 with different mass ratios of the CD38 inhibitor quercetin and the second excipient and different mass ratios of NMN and the first excipient, and the peak time difference of quercetin and NMN release in these three microspheres is consistent, all about 0.5h-1.5h.

[0206] Table 12

[0207]

[0208] Table 13

[0209]

[0210] Example 15: Experimental verification (animal experiment) on the significant improvement of NAD+ levels by controlled-release NMN microspheres with different ratios of CD38 inhibitor quercetin and excipients and different mass ratios of NMN and excipients

[0211] 28 SD rats weighing about 200g were purchased, and the experiment was conducted after one week of adaptive feeding. The 28 rats were divided into 7 groups, with 4 rats in each group (half male and half female). Group 1 received no treatment, Group 2 was gavaged with 100 mg / kg NMN, Group 3 was gavaged with 10 mg / kg quercetin, Group 4 was gavaged with 100 mg / kg NMN and 10 mg / kg quercetin at the same time, Group 5 was gavaged with controlled-release NMN microspheres 2 containing 100 mg / kg NMN and 10 mg / kg quercetin, Group 6 was gavaged with controlled-release NMN microspheres 9 containing 100 mg / kg NMN and 10 mg / kg quercetin, and Group 7 was gavaged with controlled-release NMN microspheres 10 containing 100 mg / kg NMN and 10 mg / kg quercetin.

[0212] The rats in each group were respectively given blood through the tail vein at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from the rats in each group at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Tables 14 and Fig.15 As shown: Compared with the blank group, the NMN group, quercetin group, NMN+quercetin group, controlled-release NMN microsphere 2 group, controlled-release NMN microsphere 9 group, and controlled-release NMN microsphere 10 gavage treatment group can increase the NAD+ level in rats at a certain time point. Among them, the effect of NMN+quercetin combined administration on increasing NAD+ level is better than that of NMN and quercetin alone; the effect of controlled-release NMN microsphere 2, controlled-release NMN microsphere 9, and controlled-release NMN microsphere 10 on increasing NAD+ is significantly better than that of NMN+quercetin combined administration; and there is no significant difference in the effect of controlled-release NMN microsphere 2, controlled-release NMN microsphere 9, and controlled-release NMN microsphere 10 on increasing NAD+. Due to the different mass ratios of CD38 inhibitor quercetin and excipients and the different mass ratios of NMN and excipients, there is a peak time difference in the release of quercetin and NMN in controlled release NMN microspheres 2, controlled release NMN microspheres 9 and controlled release NMN microspheres 10, and the peak time difference of quercetin and NMN release in these three microspheres is consistent, all about 0.5h-1.5h, and there is no significant difference in the effect of controlled release NMN microspheres 2, controlled release NMN microspheres 9 and controlled release NMN microspheres 10 in increasing NAD+.

[0213] Therefore, the mass ratio of CD38 inhibitor quercetin to the second excipient is 1 part: (5-15) parts, and the mass ratio of NMN to the first excipient is 5 parts: (1-10) parts. There is an obvious time difference in the peak release of quercetin and NMN in the microspheres, and the effect of enhancing NAD+ is significant, so it is a reasonable mass ratio range.

[0214] Table 14

[0215]

[0216] Example 16 Preparation of controlled-release NR microspheres with different ratios of CD38 inhibitor apigenin and excipients and different mass ratios of NR and excipients

[0217] 1. Preparation of controlled release NR microspheres 11:

[0218] The preparation process of the controlled-release NR microspheres 4 in Example 4 was used, and the mass ratio of the CD38 inhibitor apigenin to mannitol was changed to 1:5; the mass ratio of NR to hydroxypropyl methylcellulose was 5:1, and the controlled-release NR microspheres 11 were prepared. The specific steps are as follows:

[0219] (1) Take 200 g of NR and 40 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0220] (2) Take 20 g of apigenin, 100 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix well, and add to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0221] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0222] 2. Preparation of controlled release NR microspheres 12:

[0223] Using the preparation process of controlled-release NMN microspheres 4 in Example 4, the CD38 inhibitor apigenin and mannitol were mixed in a mass ratio of 1:15; NR and hydroxypropyl methylcellulose were mixed in a ratio of 5:10 to prepare controlled-release NMN microspheres 12, and the specific steps were as follows:

[0224] (1) Take 200 g of NR and 400 g of HPMC (controlled release matrix material), mix them evenly, and use purified water in a wet granulator to make a soft material. The soft material is put into an extruder spheronizer for extrusion. The sieve plate is 0.2 mm. The extruded pellets are spheronized in the spheronizer and dried to a moisture content of 3% to 5%.

[0225] (2) Take 20 g of apigenin, 300 g of mannitol (filler), and 6 g of L-HPC (disintegrant), mix well, and add to the powder feeding system of the centrifugal granulator; take 2 g of povidone K30 (binder), prepare a 5% aqueous solution with purified water, and add it to the liquid spraying system of the centrifugal granulator.

[0226] (3) Put the dried micro-pellets into the centrifugal granulator, turn on the equipment, turn on the powder feeding system, and turn on the liquid spraying system to wrap the pellet core. After wrapping, the micro-pellets are dried.

[0227] Example 17 Release verification experiment of controlled release NR microspheres with different ratios of CD38 inhibitor apigenin and excipients and different mass ratios of NR and excipients (animal experiment)

[0228] Twelve SD rats weighing about 200g were purchased, and the experiment was conducted after one week of adaptive feeding. The 12 rats were divided into 3 groups, with 4 rats in each group (half male and half female). The first group was gavaged with controlled-release NR microspheres 2, the second group was gavaged with controlled-release NR microspheres 11, and the third group was gavaged with controlled-release NR microspheres 12. The controlled-release NR microspheres gavaged with each rat in each group contained the same dose of NR, which was 100 mg / kg; the controlled-release NR microspheres gavaged with each rat in each group also contained the same dose of apigenin, which was 10 mg / kg.

[0229] The rats in each group were respectively gavaged with the corresponding microspheres at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h through the tail vein blood, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the contents of NR and apigenin in the blood samples were detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged. The results of NR content in the blood are shown in Tables 15 and Fig.16 As shown in Table 16 and Fig.17 As shown, there is a peak time difference in the release of apigenin and NR in the controlled-release NR microspheres 2, 11 and 12 with different mass ratios of CD38 inhibitor apigenin and excipients and different mass ratios of NR and excipients, and the peak time difference of apigenin and NR release in these three microspheres is consistent, all about 0.5h-1.5h.

[0230] Table 15

[0231]

[0232] Table 16

[0233]

[0234] Example 18: Experimental verification (animal experiment) on the significant improvement of NAD+ levels by controlled-release NR microspheres with different ratios of CD38 inhibitor apigenin and excipients and different mass ratios of NR and excipients

[0235] 28 SD rats weighing about 200 g were purchased, and the experiment was conducted after one week of adaptive feeding. The 28 rats were divided into 7 groups, with 4 rats in each group (half male and half female). Group 1 was not treated, Group 2 was gavaged with 100 mg / kg NR, Group 3 was gavaged with 10 mg / kg apigenin, Group 4 was gavaged with 100 mg / kg NR and 10 mg / kg apigenin at the same time, Group 5 was gavaged with controlled-release NR microspheres 2 containing 100 mg / kg NR and 10 mg / kg apigenin, Group 6 was gavaged with controlled-release NR microspheres 11 containing 100 mg / kg NR and 10 mg / kg apigenin, and Group 7 was gavaged with controlled-release NR microspheres 12 containing 100 mg / kg NR and 10 mg / kg apigenin.

[0236] Blood was collected from the tail vein of each group of rats at 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, and 6h after gavage with the corresponding microspheres, and the blood volume was 0.1ml each time. The venous blood taken from each group of rats at each time point was processed and the NAD+ content in the blood samples was detected by high performance liquid chromatography (HPLC). The test results of 4 rats in each group were averaged, and the results are shown in Tables 17 and Fig.18 As shown: Compared with the blank group, the NR group, apigenin group, NR+apigenin group, controlled-release NR microsphere 4 group, controlled-release NR microsphere 11 group, and controlled-release NR microsphere 12 gavage treatment group can increase the NAD+ level in rats at a certain time point. Among them, the effect of NR+apigenin combined administration on improving NAD+ level is better than that of NR and apigenin alone; the effect of controlled-release NR microsphere 4, controlled-release NR microsphere 11, and controlled-release NR microsphere 12 on improving NAD+ is significantly better than that of NR+apigenin combined administration; and there is no significant difference in the effect of controlled-release NR microsphere 2, controlled-release NR microsphere 11, and controlled-release NR microsphere 12 on improving NAD+. Due to the different mass ratios of CD38 inhibitor apigenin and excipients and the different mass ratios of NR and excipients, there is a peak time difference in the release of apigenin and NR in controlled release NR microspheres 4, controlled release NR microspheres 11 and controlled release NR microspheres 12, and the peak time difference of apigenin and NR release in these three microspheres is consistent, all about 0.5h-1.5h, and there is no significant difference in the effect of controlled release NR microspheres 4, controlled release NR microspheres 11 and controlled release NR microspheres 12 in increasing NAD+.

[0237] Therefore, the mass ratio of CD38 inhibitor apigenin to the second auxiliary material is 1 part: (5-15) parts, and the mass ratio of NR to the first auxiliary material is 5 parts: (1-10) parts. There is an obvious time difference in the peak release of apigenin and NR in the microspheres, and the effect of enhancing NAD+ is significant, so it is a reasonable mass ratio range.

[0238] Table 17

[0239]

[0240] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0241] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A method for improving the bioavailability of NAD+ derivatives, the method being used for non-disease diagnosis or treatment, characterized in that: The CD38 inhibitor and the NAD+ derivative are placed in the same preparation, and the CD38 inhibitor and the NAD+ derivative are controlled to be released step by step, so that the CD38 inhibitor is released first and the NAD+ derivative is released later, and the preparation is a microsphere preparation; The microsphere preparation consists of a pellet core and a coating: The pellet core is composed of the NAD+ derivative and a first auxiliary material; and The coating is wrapped on the outer surface of the pellet core, and the coating is composed of the CD38 inhibitor, the second auxiliary material and a binder; The first excipient is a controlled release skeleton excipient or a combination of a controlled release skeleton excipient and a foaming agent; The second auxiliary material is a filler and a disintegrant; The CD38 inhibitor is quercetin or apigenin; The NAD+ derivative is nicotinamide mononucleotide NMN or nicotinamide riboside NR; The mass ratio of the CD38 inhibitor to the NAD+ derivative is 20:200; The controlled release skeleton excipient is selected from at least one of the following: a hydrophilic gel skeleton material, a bioerodible skeleton material; The hydrophilic gel skeleton material is selected from at least one of the following: sodium carboxymethyl cellulose (CMC-Na), hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), and ethyl cellulose (EC); The bioerodible skeleton material is selected from hexadecanol; The filler is selected from at least one of the following: mannitol, xylitol, erythritol; The disintegrant is selected from at least one of the following: cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose (L-HPC), cross-linked sodium carboxymethyl cellulose; The binder is selected from at least one of the following: sodium carboxymethyl cellulose, povidone K30, polyethylene glycol 6000; The foaming agent is selected from sodium bicarbonate; The mass ratio of the CD38 inhibitor to the filler in the coating is 1:5 to 1:15; The mass ratio of the NAD+ derivative in the pellet core to the controlled release skeleton excipient is 5:1 to 5:10; The mass ratio of the NAD+ derivative to the first auxiliary material is 5:1-5:10; The mass ratio of the coating to the pellet core is (5-60):100; The mass ratio of the CD38 inhibitor to the second auxiliary material is 1:5-1:15; The weight ratio of the mixture of the CD38 inhibitor and the second auxiliary material to the pellet core is (5-60):100; The weight ratio of the hydrophilic gel skeleton material in the entire microsphere is 5% to 50%; The weight ratio of the bioerodible skeleton material in the entire microsphere is 3% to 20%; The peak time difference between the CD38 inhibitor and the NAD+ derivative released is 0.5 to 2 hours.

2. The method according to claim 1, characterized in that The peak time difference between the CD38 inhibitor and the NAD+ derivative released is 0.5 to 1.5 hours.